Peri-transplant ruxolitinib therapy significantly improves GVHD-free, relapse-free survival rates in transplantation for myelofibrosis (ASH 2025) - Nov 4, 2025 - Abstract #abs25-9411; 4238; Pres time: Dec 7, 2025; 06:00 PM - 08:00 PM; Location: OCCC - West Halls B3-B4; "Most patients (86%) received fludarabine/busulfan-based reduced intensity conditioning, with ATG-basedGVHD prophylaxis in all but 3 cases...Letermovir prophylaxis had no independent impact...Crucially, our results demonstrate thatperi-transplant ruxolitinib continuation appears to significantly improve composite outcomes such asGRFS without compromising engraftment. These findings support ongoing prospective evaluation of JAKinhibition as part of transplant preparation and emphasise the need for optimised donor selection andgraft composition in MF."
Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Myelofibrosis • Transplantation • CD34
|
|
Jack Illingworth1; Jennifer Clay1; Simon Bulley1; Katja Kimberger1; Chun Teh1; Marina Karakantza1; Suzanne Liebersbach1; Janette Sampson1; Gordon Cook1,2; Anjum Khan1
|